Abstract
Purpose. The aim was to explore the effect of the chromium picolinate (CrPic) administration on the pancreas and macroangiopathy of type II diabetes mellitus rats. Methods. The type II diabetes mellitus (T2DM) rat model was induced by low-dose streptozotocin (STZ). The rats were randomly divided into 5 groups (ten rats in each group). After supplementing CrPic for 15 weeks, the histopathological examination was performed by hematoxylin-eosin (HE) staining. Serum insulin and NO level were determined by radioimmunoassay and colorimetry, respectively. Serum glycosylated hemoglobin (HbA1C), adiponectin (APN), advanced glycation end products (AGES), and apelin were measured by ELISA. Real-time reverse transcription polymerase chain reaction (RT-PCR) was applied for detecting the mRNA expression of APN and apelin. Results. After CrPic treatment, compared with the T2DM control group (group 2), pancreas sections stained with HE showed the completed pancreatic cells structure and no inflammatory infiltration in groups 4 and 5. In addition, the levels of serum NO and insulin were significantly increased and the serum levels of HbA1C, AGES, APN, and apelin were significantly decreased in groups 4 and 5 compared with group 2. The mRNA expression of APN and apelin in groups 4 and 5 was also recovered to the normal level. Conclusion. CrPic can recover the function of Β-cells and alleviate macroangiopathy in STZ-induced T2DM rats.
Highlights
Diabetes mellitus (DM) is one kind of metabolic syndromes characterized by chronic hyperglycemia [1]
Macroangiopathy is the most frequent complication in the patients with T2DM [7,8,9], which manifests as atherosclerosis like in nondiabetic patients and is characterized by formation of plaques that follows in stages but with an accelerated course due to the several risk factors [10]
We evaluated the effect of Chromium picolinate (CrPic) on pancreas and macroangiopathy in T2DM rat model by detecting the levels of serum and fat markers of T2DM
Summary
Diabetes mellitus (DM) is one kind of metabolic syndromes characterized by chronic hyperglycemia [1]. There were many complications, such as nephropathy [4], cataracts [5], microangiopathy, and macroangiopathy [6] in T2DM. Macroangiopathy is the most frequent complication in the patients with T2DM [7,8,9], which manifests as atherosclerosis like in nondiabetic patients and is characterized by formation of plaques that follows in stages but with an accelerated course due to the several risk factors [10]. Western medicines are widely used to control the hyperglycemia, hyperlipidemia, and insulin resistance of type 2 diabetes mellitus, such as sulfonylurea, biguanides, thiazolidinediones, and glycosidase inhibitors [11]. It is urgently needed to explore the novel drugs and therapies to improve the treatment effect and reduce the risk of complications of T2DM
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
